期刊文献+

多基因组合荧光原位杂交在皮肤恶性黑色素瘤辅助诊断中的应用 被引量:11

Fluorescence in-situ hybridization as a diagnostic tool for cutaneous melanoma
原文传递
导出
摘要 目的 探讨多基因组合荧光原位杂交(FISH)对皮肤恶性黑色素瘤的辅助诊断价值.方法 应用黑色素瘤多基因组合FISH检测试剂盒,对20例皮肤恶性黑色素瘤和20例良性皮肤黑色素细胞痣中3个特定基因位点(CCND1、RREB1、MYB)及第6号染色体着丝粒进行检测,并按试剂盒给出标准进行结果判读.结果 共有34例标本获得满意荧光杂交信号,可准确判读FISH结果.在恶性黑色素瘤病例组,16例可准确判读FISH结果,其中FISH阳性12例,FISH阴性4例.良性黑色素细胞痣组,18例可准确判读FISH结果,其中FISH阳性1例,阴性17例.FISH检测阳性率在恶性黑色素瘤病例组远大于良性黑色素细胞痣病例组(P<0.01).结论 FISH检测对于皮肤恶性黑色素瘤的辅助诊断具有很好的特异性和较好的敏感性,有望成为皮肤黑色素瘤病理诊断和鉴别诊断的一种重要辅助方法. Objective To explore the utility of fluorescence in situ hybridization as a diagnostic tool for cutaneous melanoma.Methods Twenty cutaneous melanomas and 20 cutaneous nevi from pathology files were selected and analyzed by Vysis melanoma FISH probe kit targeting 3 loci on chromosome 6 (MYB,CEP6 and RREB1) and 1 locus on 1 1q (CCND1) and data were interpreted based on the Abbott criteria provided by the kit.Results Informative FISH results were obtained in 16 melanomas and 18 nevi.Chromosomal aberrations were detected in 12 of the 16 melanomas and only 1 of 18 nevi.Conclusion FISH is a useful diagnostic tool and able to distinguish cutaneous nevus from melanoma with good sensitivity and specificity.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2015年第1期37-41,共5页 Chinese Journal of Pathology
基金 北京高等学校青年英才计划项目(YETP0056)
关键词 黑色素瘤 原位杂交 荧光 皮肤肿瘤 Melanoma In situ hybridization,fluorescence Skin neoplasms
作者简介 通信作者:柳剑英,E—mail:liujianying@bjmu.edu.cn
  • 相关文献

参考文献18

  • 1Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century [ J]. CA Cancer J Clin, 2000,50(4) : 215-240.
  • 2Geller AC, Clapp RW, Sober AJ, et al. Melanoma epidemic: an analysis of six decades of data from the Connecticut TumorRegistry[J]. J Clin 0ncol,2013,31(33) : 4172-4178.
  • 3斯璐,郭军.新版中国黑素瘤诊治指南解读[J].临床肿瘤学杂志,2012,17(2):172-173. 被引量:18
  • 4王燕,薛卫成,斯璐,崔传亮,陆爱萍,曹登峰,郭军,李忠武.皮肤原发恶性黑色素瘤127例细胞增殖活性与生存预后相关性[J].中华病理学杂志,2013,42(3):178-181. 被引量:13
  • 5Lodha S, Saggar S, Celebi JT, et al. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting[ J 1. J Cutan Pathol, 2008,35 (4) : 349-352.
  • 6Bandarehi B, Jabbari CA, Vedadi A, et al. Molecular biology of normal melanocytes and melanoma cells[ J]. J Clin Pathol, 2013, 66 (8) : 644-648.
  • 7Gerami P, Jewefl SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma [ J 1. Am J Surg Pathol, 2009, 33 ( 8 ) : 1146-1156.
  • 8Dalton SR, Gerami P, Kolaitis NA, et al. Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma [ J ]. Am J Surg Pathol, 2010,34 (2) : 231- 237.
  • 9de Klein A, Koopmans AE, Kilic E. Muhicolor FISH with improved sensitivity and specificity in the diagnosis of malignant melanoma[J]. Expert Rev Mol Diagn, 2012,12(7) : 683-685.
  • 10LeBoit P E,Burg G,Weeclon D,et al.世界卫生组织肿瘤分类及诊断标准系列:皮肤肿瘤病理学和遗传学[M].廖松林,译.北京:人民卫生出版,2006.

二级参考文献38

  • 1步宏,郑杰.美国临床肿瘤学会/美国病理学医师学院乳腺癌HER2检测指南简介[J].中华病理学杂志,2007,36(7):496-497. 被引量:24
  • 2Berry DA,Cronin KA,Plevritis SK,et al.Effect of screening and adjuvant therapy on mortality from breast cancer[J].N Engl J Med,2005,353(17):1784-1792.
  • 3Dowsett M,Procter M,McCaskill-Stevens W,et al.Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab:the HERA trial[J].J Clin Oncol,2009,27(18):2962-2969.
  • 4Wolff AC,Hammond ME,Schwartz JN,et al.American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25 (1):118-145.
  • 5Ozzello L,DeRosa C,Habif DV,et al.An immunohistochemical evaluation of progesterone receptor in frozen sections,paraffin sections,and cytologic imprints of breast carcinomas[J].Cancer,1991,67(2):455 -462.
  • 6Kim TE,Murren JR.Lapatinib ditosylate GlaxoSmithKline[J].IDrugs,2003,6 (9):886-893.
  • 7Vogel C,Cobleigh M,Tripathy D,et al.Efficacy and safety of trastuzumab (herceptin) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer[J].J Clin Oncol,2002,20(3):719-726.
  • 8Geyer C,Forster J,Lindquist D,et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].N Engl J Med,2006,355(26):2733 -2743.
  • 9Mass R,Press M,Anderson S,et al.Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab[J].Clin Breast Cancer,2005,6(3):240 -246.
  • 10Jacobs T,Gown A,Yaziji H,et al.Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer[J].J Clin Oncol,1999,17 (7):1974-1982.

共引文献36

同被引文献40

引证文献11

二级引证文献140

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部